Submit Content Become a member
Colin Hay

EMVision Medical Devices Limited (ASX:EMV) Stage 2 interim analysis has confirmed a strong AI model performance in answering the important clinical question in acute stroke or haemorrhage.

Stage 2 has enrolled a total of 180 patients presenting to the emergency department with stroke like symptoms, across the three trial sites: Liverpool Hospital, Royal Melbourne and Princess Alexandra Hospital Brisbane.

The cross-validation evidence for interim analysis of ‘blood or not’ detection and classification, as presented below, demonstrates this desired clustering and confirms strong AI model performance in answering this important clinical question in suspected acute stroke ‘blood or not’.

The AI model is in a continuous development and integration phase and will continue to progress with data obtained in Stage 3 of the pre-validation trials, for which EMVision is currently recruiting. In addition, AI models deployed to the hardware platform have been tested to generate a detection and classification output in semi-real time following completion of a scan.

Interim analysis for the ischemia cohort is pending data processing, with further insights from the patient data collected anticipated to be shared during Stage 3 and following the completion of the pre-validation trial.

The company’s emu device’s demonstrated suitability for deployment within the streamlined code-stroke hospital protocol along with promising interim analysis of stroke diagnostic performance confirm the viability of EMVision’s disruptive modality to address key clinical requirements in acute stroke care.

“The stroke team at Princess Alexandra Hospital have found the emu scanner easy to operate in a very busy and time-pressured environment when treating people with acute stroke,” Stroke Neurologist and Principal Investigator Dr Michael Devlin said.

“We have needed to adopt only minor workflow changes to ensure no impact on the other aspects of care in the emergency department. We eagerly await the outcomes of continuing clinical trials as the impact of stroke on individuals and the community is significantly reduced with its earlier diagnosis and treatment.”

Rate article from Colin Hay: